CLNN
$6.28+0.33 (+5.46%)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinica...
Recent News
Clene Touts FDA Path for ALS Drug CNM-Au8, Highlights Biomarkers, Extends Cash Runway
Clene (NASDAQ:CLNN) executives used a conference presentation to outline near-term regulatory plans for CNM-Au8 in amyotrophic lateral sclerosis (ALS), discuss biomarker and survival analyses from prior studies, and provide an update on the company’s cash runway and financing structure. Company foc
When Will Clene Inc. (NASDAQ:CLNN) Turn A Profit?
We feel now is a pretty good time to analyse Clene Inc.'s ( NASDAQ:CLNN ) business as it appears the company may be on...
Clene Conference: FDA Grants Type C Meeting as CLNN Eyes ALS CNM-Au8 Accelerated Approval in Q2
Clene (NASDAQ:CLNN) executives told investors the clinical-stage biopharmaceutical company has secured an in-person meeting with the U.S. Food and Drug Administration (FDA) later this quarter as it continues to pursue an accelerated approval pathway for its lead program in amyotrophic lateral sclero
Institutions own 17% of Clene Inc. (NASDAQ:CLNN) shares but individual investors control 56% of the company
Key Insights The considerable ownership by individual investors in Clene indicates that they collectively have a...
Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates
Clene (CLNN) delivered earnings and revenue surprises of -41.67% and -81.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?